Cardiac Positron Emission Tomography/Computed Tomography Imaging of the Renin-Angiotensin System in Humans Holds Promise for Image-Guided Approach to Heart Failure Therapy⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Schindler, Thomas H. & Dilsizian, Vasken
P
(
v
Journal of the American College of Cardiology Vol. 60, No. 24, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.022EDITORIAL COMMENT
Cardiac Positron Emission
Tomography/Computed
Tomography Imaging of the
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Coronary artery disease (CAD) is the prevalent underlying
mechanism for the majority of patients with heart failure,
followed by idiopathic cardiomyopathy, valvular disease,
and hypertensive heart disease (1). Despite major advance-
ments in the treatment of heart failure with beta-blockers,
angiotensin-converting enzyme (ACE) inhibition, angio-
tensin II type 1 receptor (AT-1) blockers, and aldosterone
that impact morbidity and mortality, 5-year mortality rates
for heart failure still remain as high as 50%. In the United
States, more than 4 million people suffer from heart failure
(2), and in view of an increasingly elderly population, the
prevalence of this disease is likely to continuously increase.
See page 2527
Left ventricular (LV) remodeling, defined clinically as
alterations in volume, shape, and/or function of the heart
chambers in response to chronically elevated loading con-
ditions, has been appreciated as a central determinant of the
clinical course and outcome of systolic heart failure. Apart
from the catecholamine actions and the development of
interstitial myocardial fibrosis, the myocardial renin-
angiotensin system (RAS) has been closely related to the
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parallel LV remodeling. LV remodeling is characterized by
limited hypertrophic growth, remodeling of cardiac myo-
cytes with reactivation of fetal gene program, progressive
loss of contractile proteins, defective excitation-contracting
coupling, interstitial fibrosis, and a decreased responsiveness
to beta-adrenergic stimulation (3). Despite such adaptive
myocardial alterations to produce more efficient oxygen
consumption, better energy generation, and prolonged cell
survival, there is a continuous cell loss during the cardiac
remodeling process via necrotic, apoptotic, and most likely,
autophagic pathways (3). Not surprisingly, numerous large
randomized clinical trials have demonstrated direct benefi-
cial effects of RAS blockade on clinical symptoms and
outcomes of patients with LV systolic dysfunction (2). ACE
inhibitors, AT-1 blockers, and aldosterone antagonists have
been successfully applied to prevent or at least delay LV
remodeling associated with a marked improvement in clin-
ical symptoms, reduction in hospitalization, and mortality
rates in patients with systolic dysfunction. Conversely, it has
also been recognized that a marked interindividual variabil-
ity in response to RAS blockade may exist, ranging from
distinct clinical benefit to no detectable benefit and even to
serious adverse reactions (4). The underlying mechanisms
for the described variety in individual responses to medical
heart failure therapy remains uncertain, but they have been
related to differences in race, ethnicity, comorbid condi-
tions, concomitant use of other medications, and certain
genetic predispositions (3,5). Another potential mechanism
for the large variability in individual responses to the
inhibition of the RAS may be seen in the myocardial tissue
component of the RAS, which is largely independent of its
systemic component and not accessible to routine laboratory
testing (6). In view of the described variability in myocardial
response to medical RAS blockade, the identification and
characterization of the myocardial tissue component or the
RAS system with molecular imaging in the individual heart
failure patient is highly desirable (Table 1). It is anticipated
that such a diagnostic approach would provide more precise
information to predict and monitor the myocardial response
to medical RAS blockade.
Targeting cardiac angiotensin II type I receptors. In this
issue of the Journal, Fukushima et al. (7) describe a novel
AT-1 receptor ligand [11C]-KR31173 combined with
ET/CT that targets the angiotensin II subtype 1 receptor
AT1R) of the human heart. As it was observed in 4 healthy
olunteers, myocardial retention of [11C]-KR31173 was
visually detectable, homogenously distributed in the myo-
cardium, and stable over time. However, it is important to
note that myocardial retention of KR31173 in these healthy
human subjects was significantly lower than those in normal
healthy pigs (1.2  0.1%/min vs. 4.4  1.2%/min). More-
over, after pre-treatment with olmesartan, only 54% of the
receptors (1.3  0.1%/min to 0.7  0.1%/min) were
blocked, suggesting limited specificity. Nonetheless, this
c
t
t
w
f
m
i
F
m
s
(
a
s
i
c
s
p
w
e
b
b
[
s
o
a
A
l
s
2536 Schindler and Dilsizian JACC Vol. 60, No. 24, 2012
Cardiac PET/CT Imaging, Renin-Angiotensin System December 18, 2012:2535–8first-in-man application of receptor ligand [11C]-KR31173
ombined with PET/CT confirmed the presence of local
issue RAS in human hearts, proved to be safe, and showed
hat the signal was high enough to allow external imaging
ith PET. Additional experiments performed in young
arm pigs under healthy conditions and 3 to 4 weeks after
yocardial infarction showed AT1R up-regulation in the
nfarcted area when compared with remote myocardium.
urther, the retention of KR31173 in infarcted and remote
yocardium (8.7  0.8%/min and 7.1  0.3%/min) was
ignificantly higher than in the myocardium of healthy pigs
5.8  0.4%/min). In postmortem immunohistochemistry
nalysis, anti-AT1R antibody binding was localized to
pindle-shaped cells, presumably myofibroblasts, in the
nfarct region, whereas there was also significant binding to
ardiomyocytes in remote areas. These findings in pigs are
imilar to those observed in an experimental mouse model of
ost-infarction heart failure in which in vivo AT1R imaging
as accomplished with 99mTc losartan micro–single-photon
mission CT/CT and immunohistochemical analysis showed
Molecular Radiotracers ThatTarget the Renin-Angiotensin SystemTable 1 Molecula Radiotracers ThatTarget the Renin-Angiotensin System
Angiotensin-Converting Enzyme Angiotensin II Type 1 Receptor
18F-fluorocaptopril 11C-MK-996
11C-zofenoprilat 11C-L-159884
125I-iodotyrosyl-lisinopril 11C-KR31173
18F-fluorobenzoyl-lisinopril 99mTc-losartan
99mTc-(CO)3D(C8)-lisinopril
Figure 1 Diagrammatic Representation of Myocardial Cell and
and Mapping of the Surface RAS
ACE  angiotensin-converting enzyme; AGT  angiotensinogen; Ang II  angiotensin II; AT
mRNA  messenger RNA; RAS  renin-angiotensin system.inding of the radiotracer almost exclusively in the myofi-
roblast rather than cardiomyocytes (8). Thus, although the
11C]-KR31173 imaging signal identifies AT1R expression
in the myocardium, it does not differentiate between myo-
fibroblast and cardiomyocyte cell types, and with 54% of the
receptors blocked after pre-treatment with an AT-1
blocker, it has limited specificity. In this direction, the
combination with other molecular imaging probes, such
as radiolabeled ACE inhibitors to investigate the LV
remodeling process could prove to be useful in heart
failure patients (Fig. 1).
Targeting cardiac ACE. An alternative molecular imaging
strategy is to image and monitor myocardial ACE-1 up-
regulation as a function of progressive heart failure. ACE-1
is a large type I anchored glycoprotein that is located
extracellularly along the surface of the myocardial cell
membrane. ACE inhibitors bind to these extracellular
enzyme binding sites and in large clinical trials have shown
to improve patient mortality, prevent or reverse LV remod-
eling, and improve quality of life (9–11). External cardiac
imaging using radiolabeled ACE inhibitors may give a
direct measure of tissue ACE expression in the myocar-
dium. High-affinity 18F-fluorobenzoyl-lisinopril has been
hown to specifically localize in ex vivo myocardial samples
btained from explanted cardiomyopathic hearts in cardiac
llograft recipients by autoradiography (12,13). In human
CE-1 overexpressing transgenic rats, technetium-99m–
abeled lisinopril was shown to provide a signal intensity that is
ufficiently high to allow external micro–single-photon emis-
ntial Targets of Radiotracer Imaging
angiotensin II type 1 receptor; AT2R  angiotensin II type 2 receptor;Pote
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the RAS process starts early in the failing heart with
activation of the ACE-1 activity within the cardiomyocytes
(16,17) rather than the downstream effects of angiotensin II
on AT1R, targeting the imaging to ACE itself could be
more sensitive (Fig. 1). Moreover, ACE to Ang II produc-
tion is independent of AT1R regulation, which could make
ACE imaging more specific.
Imaging patients with heart failure. As the authors ac-
knowledge, the feasibility and diagnostic value of RAS
imaging in heart failure patients due to myocardial infarc-
tion or other pathological conditions remain to be tested.
Although high-affinity radiotracers provide high target-to-
nontarget ratios in vivo with specific binding to a target
protein, in disease states such as heart failure, it is perhaps
more important to develop a probe at high specific activity
that is sensitive to changes in target protein as a function of
disease or treatment. Accordingly, it is ultimately the Bmax
(total available target protein), Bmax/KD (ratio of target
ensity to equilibrium dissociation constant), and receptor
ccupancy of these radiotracers that will determine the
est-suited potential probe for in vivo imaging of heart
ailure patients. Maximum in vivo binding potential of a
adiotracer can also be influenced by other factors, such as
onspecific binding, free fraction either in plasma or in the
arget milieu, the exclusion of metabolites, and specific
inding to other targets (17). Beyond the radiopharmaceu-
ical design and characterization, the regulation of AT1R
nd recycling and/or degradation of AT-1 receptor are key
o imaging. Receptor expression can be altered from normal
o diseased state, and can be affected by a multitude of
actors, and in any one of the steps of transcription,
ranslation, or trafficking.
ACE-1 imaging with high-affinity 99mTc–labeled lisino-
ril, as another myocardial tissue RAS imaging probe, may
rovide invaluable information in identifying other molec-
lar mechanisms leading to the initiation and progression of
ystolic heart failure upstream of the myocardial AT-1
eceptors (14). Such a hybrid molecular imaging approach
ould contribute to a better understanding of the effects of
CE inhibition alone or in combination with AT-1 block-
rs on LV hypertrophy in hypertensive patients (18) and
ay further elucidate the link between renal and cardiovas-
ular disease (19). In addition, for a comprehensive evalu-
tion of the RAS in heart failure patients, research activities
hould also be directed to image the expression of angio-
ensin II type 2 receptors in the myocardium. The develop-
ent of such molecular imaging probes to potentially
ersonalize and guide the medical treatment of heart failure
atients appears of utmost importance because the promise
as not yet been mitigated by a decade of investigation with
iomarkers, such as pro-brain natriuretic peptide or cardiac
roponin T, and genomics (2).
onclusions. The work published by Fukushima et al. (7)
epresents an important translational step of previous exper-
mental investigations for identification and characterizationf AT1R expression in the normal human heart, whose
pplication in heart failure patients, however, remains un-
ested. Such image-guided molecular approach holds prom-
se to ultimately enable earlier and more precise identifica-
ion and characterization of heart failure, and the
ssessment and monitoring of the therapeutic responses in
ndividual patients. Whether such image-guided and per-
onalized medical intervention aiming to prevent or delay
he progression of LV remodeling will ultimately result in
mproved patient outcome requires clinical verification.
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